Neuren Pharmaceuticals Ltd (ASX: NEU) Share Price and News
Price
–
Movement
– ( )
(20 mins delayed)
52 Week Range
– - –
1 Year Return
Neuren Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
–
Day Change
– ( )
52 Week Range
– - –
Yesterday's Close
–
Today's Open
–
Days Range
– - –
Volume
–
Avg. Volume (1 month)
–
Turnover
–
Neuren Pharmaceuticals Ltd (ASX: NEU)
Latest News
Growth Shares
3 fantastic ASX 200 growth shares to buy in 2025
Growth Shares
Invest $5,000 into these ASX 200 shares in 2025
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Growth Shares
My 2 best ASX growth shares to buy in November
Growth Shares
These ASX 200 growth shares could rise 50% to 60%
Best Shares
Here are the best-performing ASX 200 shares since the US election result
Share Market News
Here are the top 10 ASX 200 shares today
Healthcare Shares
3 ASX healthcare shares going gangbusters on Thursday
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Why ANZ, Block, Neuren, and Pilbara Minerals shares are pushing higher today
Healthcare Shares
Buy this ASX 200 share that is swimming in cash
Frequently Asked Questions
-
No, Neuren Pharmaceuticals does not pay dividends at this time.
-
Neuren Pharmaceuticals Limited (ASX: NEU) listed on the ASX on 3 February 2005.
NEU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|
About Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells.
In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.
Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi.
Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.
NEU Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 12 May 2025 | $12.02 | $-1.27 | -9.56% | 1,490,963 | $12.89 | $12.89 | $11.97 |
| 09 May 2025 | $13.29 | $0.49 | 3.83% | 757,061 | $13.19 | $13.49 | $12.81 |
| 08 May 2025 | $12.80 | $0.18 | 1.43% | 1,193,552 | $12.60 | $12.89 | $12.11 |
| 07 May 2025 | $12.62 | $0.47 | 3.87% | 752,028 | $12.05 | $12.70 | $12.03 |
| 06 May 2025 | $12.15 | $-0.15 | -1.22% | 359,857 | $12.30 | $12.51 | $12.13 |
| 05 May 2025 | $12.30 | $-0.14 | -1.13% | 630,459 | $12.60 | $12.73 | $12.10 |
| 02 May 2025 | $12.44 | $0.64 | 5.42% | 606,889 | $11.74 | $12.79 | $11.67 |
| 01 May 2025 | $11.80 | $0.14 | 1.20% | 455,202 | $11.70 | $11.98 | $11.61 |
| 30 Apr 2025 | $11.66 | $0.10 | 0.87% | 608,951 | $11.65 | $11.72 | $11.36 |
| 29 Apr 2025 | $11.56 | $0.57 | 5.19% | 677,157 | $11.00 | $11.62 | $10.92 |
| 28 Apr 2025 | $10.99 | $-0.35 | -3.09% | 560,080 | $11.43 | $11.59 | $10.99 |
| 24 Apr 2025 | $11.34 | $0.33 | 3.00% | 493,618 | $11.16 | $11.59 | $11.16 |
| 23 Apr 2025 | $11.01 | $0.62 | 5.97% | 550,515 | $10.81 | $11.27 | $10.61 |
| 22 Apr 2025 | $10.39 | $-0.14 | -1.33% | 458,821 | $10.45 | $10.67 | $10.32 |
| 17 Apr 2025 | $10.53 | $0.36 | 3.54% | 672,718 | $10.11 | $10.53 | $10.11 |
| 16 Apr 2025 | $10.17 | $-0.81 | -7.38% | 852,200 | $10.86 | $10.95 | $10.10 |
| 15 Apr 2025 | $10.98 | $-0.15 | -1.35% | 1,102,530 | $11.20 | $11.63 | $10.51 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 16 Apr 2025 | Joseph(Joe) Basile | Buy | 14,500 | $153,158 |
On-market trade.
|
| 16 Aug 2024 | Joseph(Joe) Basile | Buy | 6,406 | $100,766 |
On-market trade.
|
| 11 Jun 2024 | Joseph(Joe) Basile | Buy | 5,000 | $97,450 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Dianne Margaret Angus | Non-Executive Director | Jul 2018 |
Ms Angus has executive managerial and company director experience in the biotechnology, biopharmaceutical, medical device, agritech and healthcare industries. Dianne has created global industry partnerships to yield medical, pharmaceutical and agricultural products. She has also driven the development path for novel neurological pre-clinical agents to late stage clinical assets before the FDA and European regulators. With over twenty five year' experience in ASX and NASDAQ listed companies, she has experience in business development, capital raising and investor relations together with corporate governance and compliance capabilities. She is also a council member of Deakin University.
|
| Mr Jonathan (Jon) Charles Pilcher | Chief Executive OfficerManaging Director | Aug 2013 |
Mr Pilcher has played a central role in all aspects of Neuren's R&D, commercial and corporate activities. Before joining Neuren he was a member of the leadership team at Acrux throughout a period that included Acrux's IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of executive positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB.
|
| Dr Jenny Lee Harry | Non-Executive Director | Jul 2018 |
Dr Harry has 20 years' experience in executive management of companies in the biotechnology and biopharmaceutical industry and is an accomplished CEO and Managing Director with experience in growing companies from start-up to commercialisation. She has served on Boards of a number of listed and unlisted companies and is currently a Non-Executive Director of Lumitron Technologies Inc.
|
| Mr Patrick Davies | Non-Executive DirectorNon-Executive Chairman | Jul 2018 |
Mr Davies has held executive management roles in the Australian and New Zealand healthcare industry for over twenty five years having performed in senior roles across industry sectors including pharmacy, primary care, pharmaceutical and consumer products. During his ten year period as Chief Executive Officer of EBOS Group Limited (and previously Symbion), the enterprise value of the group achieved compound annual growth in enterprise value of +20% (from circa $450M to in excess of $3.1B). He is a director on other corporate boards and provides strategic advice to a range of healthcare businesses and investors.
|
| Mr Joseph(Joe) Basile | Non-Executive Director | Mar 2023 |
Mr Basile has held a number of executive roles in the pharmaceutical industry for over 30 years, most recently as Group CFO at iNova Pharmaceuticals based in Singapore and prior to that with Novartis in senior Finance leadership and Commercial Sales leadership roles in Australia and Asia.
|
| Ms Lauren Frazer | Chief Financial OfficerCompany Secretary | Aug 2020 |
-
|
| Gerry Zhao | Chief Business Officer |
-
|
|
| Lauren Frazer | Chief Financial OfficerCompany Secretary |
-
|
|
| Liza Squires | Chief Medical Officer |
-
|
|
| Clive Blower | Chief Operations Officer |
-
|
|
| Larry Glass | Chief Science Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 17,684,031 | 13.97% |
| Citicorp Nominees Pty Limited | 13,225,277 | 10.45% |
| J P Morgan Nominees Australia Pty Limited | 12,906,867 | 10.20% |
| Cameron Richard Pty Ltd | 4,355,222 | 3.44% |
| BNP Paribas Noms Pty Ltd | 4,056,178 | 3.20% |
| Stuart Andrew Pty Ltd | 2,790,348 | 2.20% |
| Essex Castle Limited | 2,322,678 | 1.83% |
| Linwierik Super Pty Ltd | 1,800,000 | 1.42% |
| Smithley Super Pty Ltd | 1,584,000 | 1.25% |
| Sharesies Australia Nominee Pty Limited | 1,497,609 | 1.18% |
| National Nominees Limited | 1,143,545 | 0.90% |
| First Colbyco Pty Ltd | 829,200 | 0.65% |
| BNP Paribas Nominees Pty Ltd | 765,775 | 0.60% |
| Dr Robin Lance Congreve | 671,637 | 0.53% |
| Mjhft Pty Ltd | 600,000 | 0.47% |
| Netwealth Investments Limited | 560,073 | 0.44% |
| Custodial Services Limited | 554,271 | 0.44% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 490,918 | 0.39% |
| Emancipayte Pty Ltd | 463,141 | 0.37% |
| BNP Paribas Nominees Pty Ltd i | 434,135 | 0.34% |